4.95
price up icon1.23%   0.06
after-market Handel nachbörslich: 4.95
loading

Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten

pulisher
03:07 AM

Deal Dispatch: US M&A Is Quiet, But Abroad? Volume Is Spiking - Benzinga

03:07 AM
pulisher
02:38 AM

Gene Therapy Market Demand, Growth and Future Scope 2025-2032 | - openPR.com

02:38 AM
pulisher
Apr 02, 2025

Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease - Business Wire

Apr 02, 2025
pulisher
Mar 31, 2025

BlueBird Shares Are Up Today: What's Going On? - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumpsbluebird bio (NASDAQ:BLUE) - Benzinga

Mar 31, 2025
pulisher
Mar 31, 2025

Bluebird Bio Receives $4.50 Per Share Acquisition Proposal From Ayrmid - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

bluebird bio’s SWOT analysis: biotech firm’s stock faces cash crunch, product potential - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Bluebird bio rises on non-binding bid for up to $110.5 million - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Bluebird bio receives non-binding bid for up to $110.5 million - MSN

Mar 31, 2025
pulisher
Mar 29, 2025

Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more - MSN

Mar 29, 2025
pulisher
Mar 29, 2025

Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more (T:NYSE) - Seeking Alpha

Mar 29, 2025
pulisher
Mar 29, 2025

bluebird bio confirms rival takeover bid - The Pharma Letter

Mar 29, 2025
pulisher
Mar 29, 2025

Bluebird Bio Stock Leaps On Ayrmid Offer Amid Financial Strain - Finimize

Mar 29, 2025
pulisher
Mar 29, 2025

Bluebird Bio Draws New Bid, Sending Shares Climbing - Finimize

Mar 29, 2025
pulisher
Mar 28, 2025

Ayrmid Proposes to Acquire Bluebird Bio, Inc. (BLUE) with Premiu - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

New suitor emerges for struggling bluebird bio - FirstWord Pharma

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio (BLUE) Receives Acquisition Offer from Ayrmid - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio receives rival M&A bid worth 50% higher than Carlyle-SK offer - Fierce Pharma

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio (BLUE) Receives Higher Bid from Ayrmid Pharma - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio sees higher offer for company from Ayrmid Pharma - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio (BLUE) Receives Higher Buyout Bid from Ayrmid - GuruFocus

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio receives higher acquisition offer from Ayrmid - Investing.com India

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio shares rally 11% in late trade on buyout offer - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio receives higher acquisition offer from Ayrmid By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio reports another acquisition offer for $45M upfront - The Business Journals

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio Gets Rival Buyout Proposal From Ayrmid; Shares Jump After Hours - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio stock rises on new acquisition proposal By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird bio stock rises on new acquisition proposal - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio confirms receipt non-binding proposal from Ayrmid - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Bluebird Bio Confirms Receipt Of An Unsolicited Non-Binding Proposal From Ayrmid - Marketscreener.com

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid - Business Wire

Mar 28, 2025
pulisher
Mar 28, 2025

Sickle Cell Treatment Market Business Outlook and Growth - openPR

Mar 28, 2025
pulisher
Mar 28, 2025

bluebird bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 26, 2025

T-Cell Immunotherapy Market is Booming Worldwide |Medigene,Bluebird Bio,Novartis - openPR

Mar 26, 2025
pulisher
Mar 24, 2025

Sickle Cell Disease Treatment Market: New Drug Approvals - openPR

Mar 24, 2025
pulisher
Mar 21, 2025

Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – BLUE - Business Wire

Mar 21, 2025
pulisher
Mar 21, 2025

Gene therapy loses luster as investors eye quicker returns from weight-loss drugs - Reuters

Mar 21, 2025
pulisher
Mar 21, 2025

Drug developers show mixed performance in early 2025 - BioWorld Online

Mar 21, 2025
pulisher
Mar 21, 2025

Sickle Cell Disease Pipeline 2025 Detailed Clinical Trials - openPR

Mar 21, 2025
pulisher
Mar 18, 2025

Carlyle's bluebird Deep Discount Buyout (Rating Upgrade) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc.BLUE - PR Newswire

Mar 17, 2025
pulisher
Mar 14, 2025

Gene therapy efforts active, despite low Bluebird, 2seventy bids - BioWorld Online

Mar 14, 2025
pulisher
Mar 13, 2025

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire

Mar 13, 2025
pulisher
Mar 13, 2025

Gene Therapy Market Future Business Opportunities 2025-2032 | - openPR

Mar 13, 2025
pulisher
Mar 12, 2025

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal - Dealbreaker

Mar 12, 2025
pulisher
Mar 12, 2025

Bluebird’s Go-Private Deal Highlights Fraught Life Preserver for Struggling Biotechs - BioSpace

Mar 12, 2025
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):